Biomarkers in Patients With Respiratory Tract Dysplasia or Lung Cancer, Head and Neck Cancer, or Aerodigestive Tract Cancer and in Normal Volunteers
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT00900419 |
Recruitment Status
:
Recruiting
First Posted
: May 12, 2009
Last Update Posted
: August 30, 2017
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
RATIONALE: Studying samples of sputum and tissue in the laboratory from patients with dysplasia or cancer and from normal volunteers may help doctors identify and learn more about biomarkers related to cancer. It may also help the study of cancer in the future.
PURPOSE: This laboratory study is looking at biomarkers in patients with respiratory tract dysplasia or lung cancer, head and neck cancer, or aerodigestive tract cancer and in normal volunteers.
Condition or disease | Intervention/treatment |
---|---|
Esophageal Cancer Head and Neck Cancer Lung Cancer Precancerous Condition | Other: immunohistochemistry staining method Other: laboratory biomarker analysis Other: sputum cytology Procedure: biopsy |
OBJECTIVES:
Primary
- Determine intermediate biomarkers of premalignant respiratory epithelial lesions, such as genetic mutations or altered growth factor expression, in patients with dysplasia of the respiratory epithelium or lung cancer, head and neck cancer, or aerodigestive tract cancer.
Secondary
- Establish a tissue repository of normal and dysplastic respiratory epithelium from endobronchial forceps and brush biopsy tissue from these patients and from normal volunteers.
OUTLINE: Patients are stratified according to presence of extensive and severe dysplasia of the respiratory epithelium (yes vs no).
Participants undergo sputum cytology, white-light (with or without fluorescence) bronchoscopy, and endobronchial biopsies. Participants also undergo endobronchial brushings and bronchial secretion collection and possibly bronchoalveolar lavage. Collected samples are processed by hematoxylin, eosin, and immunohistochemical staining and analyzed for specific biomarkers. Unused samples are stored in the tissue bank.
PROJECTED ACCRUAL: A total of 330 participants will be accrued for this study.
Study Type : | Observational |
Estimated Enrollment : | 500 participants |
Observational Model: | Other |
Time Perspective: | Prospective |
Official Title: | Biomarkers and Dysplastic Respiratory Epithelium |
Study Start Date : | March 2002 |
Estimated Primary Completion Date : | May 2018 |
Estimated Study Completion Date : | May 2018 |

-
Other: immunohistochemistry staining method
- Genetic mutations or altered growth factor expression [ Time Frame: After study has completed ]
- Establishment of a tissue repository of normal and dysplastic respiratory epithelium [ Time Frame: After study has closed ]
Biospecimen Retention: Samples With DNA

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 21 Years to 90 Years (Adult, Senior) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | Yes |
Sampling Method: | Non-Probability Sample |
DISEASE CHARACTERISTICS:
-
Meets any of the following criteria:
-
Diagnosis of extensive and severe dysplasia of the respiratory epithelium
- Recruited from the SPORE Tissue Procurement Screening Project or by private or academic physicians (for patients with moderate or severe dysplasia)
- Survived 1 or more aerodigestive system carcinoma for ≥ 1 year
- Completely resected stage I non-small cell cancer
-
Undergoing any of the following procedures:
- Routine panendoscopy for patients with head and neck cancer
- Resection of a bronchogenic carcinoma
- Bronchoscopy for diagnosis or staging of suspected lung cancer
- Subsequent bronchoscopy for surveillance or monitoring of response to endobronchial treatment in patients with prior high-grade dysplasia or worse
-
No dysplasia (normal volunteers)
- No asthma
- No lung disease
- No respiratory illness within the past 2 weeks Patients suspected of or at risk for neoplastic lung disease who are undergoing a bronchoscopy in which differential diagnostic considerations may include multiple other etiologies such as infection and other processes.
-
PATIENT CHARACTERISTICS:
- No clinically apparent bleeding diathesis
- No known bleeding disorder
- No anginal
- No clinically active coronary artery disease
- No multifocal premature ventricular contractions
- No poorly controlled congestive heart failure
- No myocardial infarction within the past 6 weeks
- No cardiac dysrhythmia that is potentially life threatening
- Well-controlled atrial fibrillation or rare (< 2/min) premature ventricular contractions allowed
- No ventricular tachycardia or supraventricular tachycardia with a rapid ventricular response
- No other serious medical condition that would preclude a patient from undergoing a bronchoscopy
- No acute bronchitis or pneumonia within the past 8 weeks except when clinically proven as a possible result of lung cancer
- No hypoxemia (i.e., < 90% saturation with supplemental oxygen) before bronchoscopy
PRIOR CONCURRENT THERAPY:
- See Disease Characteristics

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00900419
United States, Colorado | |
University of Colorado Cancer Center at UC Health Sciences Center | Recruiting |
Aurora, Colorado, United States, 80045 | |
Contact: Clinical Trials Office - University of Colorado Cancer Center 303-724-1650 |
Principal Investigator: | York E. Miller, MD | University of Colorado, Denver |
Responsible Party: | University of Colorado, Denver |
ClinicalTrials.gov Identifier: | NCT00900419 History of Changes |
Other Study ID Numbers: |
00-1108 SPORE 24 ( Other Identifier: SPORE Number ) P50CA058187 ( U.S. NIH Grant/Contract ) |
First Posted: | May 12, 2009 Key Record Dates |
Last Update Posted: | August 30, 2017 |
Last Verified: | August 2017 |
Keywords provided by University of Colorado, Denver:
non-small cell lung cancer small cell lung cancer squamous lung dysplasia hypopharyngeal cancer laryngeal cancer lip and oral cavity cancer metastatic squamous neck cancer with occult primary |
nasopharyngeal cancer oropharyngeal cancer paranasal sinus and nasal cavity cancer salivary gland cancer esophageal cancer pulmonary carcinoid tumor tongue cancer |
Additional relevant MeSH terms:
Lung Neoplasms Head and Neck Neoplasms Esophageal Neoplasms Precancerous Conditions Respiratory Tract Neoplasms Thoracic Neoplasms Neoplasms by Site Neoplasms |
Lung Diseases Respiratory Tract Diseases Gastrointestinal Neoplasms Digestive System Neoplasms Digestive System Diseases Esophageal Diseases Gastrointestinal Diseases |